Global House Dust Mite Allergy Market Segments 2024, Forecast To 2033
5 Mar, 2024
The house dust mite allergy market has witnessed rapid growth, increasing from $1.9 billion in 2023 to $2.18 billion in 2024, with a 14.9% CAGR. The historic period's growth is attributed to awareness, diagnostic advancements, research, healthcare infrastructure, and regulatory standards. Expecting rapid growth, the market is projected to reach $3.69 billion in 2028 with a 14.0% CAGR. This growth is driven by regulatory support, allergy prevalence, telemedicine, precision medicine focus, and allergen-avoidance product expansion, accompanied by trends like public health campaigns and digital health integration.
Global House Dust Mite Allergy Market Key Driver
The house dust mite allergy market is driven by the rising prevalence of asthma, with a 149% surge in hospital admissions for children in England and Wales. The London School of Hygiene and Tropical Medicine and Asthma + Lung UK underscore the market's growth due to increased asthma cases.
Get A Free Sample Of The Global House Dust Mite Allergy Market ReportGlobal House Dust Mite Allergy Market Segments
The house dust mite allergy market covered in this report is segmented –
1) By Product Type: Tablets, Nasal Drops, Injectable
2) By Treatment Type: Medication, Immunotherapy, Nasal Irrigation, Other Types
3) By Diagnosis: Skin Prick Test (SPT), Specific Immunoglobulin E (IgE) Blood Test, Other Diagnosis
4) By Dosage Forms: Solid, Liquid
5) By End Users: Hospitals, Homecare, Specialty Clinics, Other End Users
By Geography: The regions covered in the anti inflammatory therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe,North America, South America, Middle East, and Africa. Among these regions.
North America was the largest region in the house dust mite allergy market in 2023. Asia-pacific is expected to be the fastest-growing region in the house dust mite allergy market report during the forecast period. The regions covered in the house dust mite allergy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Major House Dust Mite Allergy Industry Players
Allergy Therapeutics Plc; Bayer AG; Catalent Inc.; GSK Plc; Merz Pharma GmbH & Co KGaA; Sanofi S A; Shionogi & Co. Ltd.; Stallergenes Greer International AG; Merck & Co. Inc.; Torii Pharmaceutical Co. Ltd.; Ergomed PLC; DMS Group; HAL Allergy Group; Trio Lifescience Private Limited; Teva Pharmaceutical Industries Ltd.; Eli Lilly and Company; Genentech Inc.; Anergis Sa; Biomay Ag; Zhejiang I-biological Technology Co. Ltd.; Johnson and Johnson Inc.; Boehringer Ingelheim International GmbH; Circassia Pharmaceuticals Plc; Seqirus UK Limited; GlaxoSmithKline; Novartis AG; AstraZeneca; Bristol-Myers Squibb Company; Mylan N.V.; Pfizer Inc.; Regeneron Pharmaceuticals Inc.; Roche Holding AG
Get The Full Global House Dust Mite Allergy Market Report
AIOps House Dust Mite Allergy Market Overview
House dust mite allergy refers to an allergic reaction to small insects that frequently reside in household dust. This includes the treatment provided for allergic reactions such as sneezing and allergy-related conditions.
House Dust Mite Allergy Global Market Report 2023 provides data on the global house dust mite allergy market such as market size, growth forecasts, segments and geographies, competitive landscape including leading competitors’ revenues, profiles and market shares. The house dust mite allergy market report identifies opportunities and strategies based on market trends and leading competitors’ approaches.